Mekonos develops a proprietary cell-engineering platform that utilizes microfluidic technology to facilitate the creation of cell therapies on a chip. This approach enables precise manipulation of cellular environments, improving the efficiency and scalability of therapeutic development.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FVP6Founders
Product
Problem
Cell therapy development is often limited by inefficient and inconsistent cell engineering processes. Traditional methods lack the precision and control needed to optimize cellular environments, hindering the scalability and effectiveness of therapeutic development.
Solution
Mekonos is developing a cell-engineering platform leveraging microfluidic technology to create cell therapies on a chip. This approach enables precise manipulation of cellular environments, leading to improved efficiency and scalability in therapeutic development. By miniaturizing and automating cell handling, Mekonos aims to provide a more controlled and reproducible environment for cell modification and analysis. This technology has the potential to accelerate the discovery and manufacturing of novel cell-based therapies.
Target Audience
The primary target audience includes cell therapy developers, pharmaceutical companies, and research institutions involved in developing cell-based therapeutics.
Features
- Microfluidic cell-engineering platform for precise control of cellular environments
- Automated cell handling and manipulation
- Enhanced scalability of cell therapy development
- Improved efficiency in cell modification and analysis